[{"id":"5949ed40-8066-4fa3-b731-56d11b1c4969","acronym":"MRT-2359-001","url":"https://clinicaltrials.gov/study/NCT05546268","created_at":"2022-09-19T13:55:51.266Z","updated_at":"2025-02-25T14:17:16.661Z","phase":"Phase 1/2","brief_title":"Study of Oral MRT-2359 in Selected Cancer Patients","source_id_and_acronym":"NCT05546268 - MRT-2359-001","lead_sponsor":"Monte Rosa Therapeutics, Inc","biomarkers":" MYC • MYCN","pipe":" | ","alterations":" MYCN amplification • MYC expression","tags":["MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • MRT-2359"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-17"},{"id":"61d56240-acd7-4036-be44-40ad727ab77a","acronym":"A051701","url":"https://clinicaltrials.gov/study/NCT03984448","created_at":"2021-01-18T19:35:47.901Z","updated_at":"2025-02-25T15:11:12.787Z","phase":"Phase 2/3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","source_id_and_acronym":"NCT03984448 - A051701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 363","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-13"},{"id":"7246a629-768b-4557-b16c-b951baaa4ed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03742258","created_at":"2021-01-18T18:19:49.340Z","updated_at":"2025-02-25T15:34:14.094Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03742258","lead_sponsor":"Northwestern University","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • mivavotinib (CB-659) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 03/12/2021","primary_completion_date":" 03/12/2021","study_txt":" Completion: 12/19/2028","study_completion_date":" 12/19/2028","last_update_posted":"2025-02-11"},{"id":"6197c2dd-dcac-48ae-964b-1bb53f9a93dc","acronym":"FOG-001-101","url":"https://clinicaltrials.gov/study/NCT05919264","created_at":"2023-06-26T14:09:21.574Z","updated_at":"2024-07-02T16:34:36.852Z","phase":"Phase 1/2","brief_title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05919264 - FOG-001-101","lead_sponsor":"Fog Pharmaceuticals, Inc.","biomarkers":" MSI • CTNNB1","pipe":" | ","alterations":" MYC expression","tags":["MSI • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zolucatetide (FOG-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 08/31/2027","study_completion_date":" 08/31/2027","last_update_posted":"2024-06-10"},{"id":"700dc8c9-7994-4f0c-9f97-a10c4b36a1dd","acronym":"GO43075","url":"https://clinicaltrials.gov/study/NCT04980222","created_at":"2021-07-28T19:52:29.789Z","updated_at":"2024-07-02T16:34:58.915Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04980222 - GO43075","lead_sponsor":"Hoffmann-La Roche","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD20 positive • MYC expression • BCL6 translocation","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • MYC expression • BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-04"},{"id":"bb4e6c88-c7d9-42ab-942f-08dd0a63585b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06357338","created_at":"2024-04-10T17:42:48.293Z","updated_at":"2024-07-02T16:35:10.258Z","phase":"","brief_title":"Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma","source_id_and_acronym":"NCT06357338","lead_sponsor":"Marwa Mahmoud Hassan","biomarkers":" MYC","pipe":" | ","alterations":" MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 70","initiation":"Initiation: 03/19/2024","start_date":" 03/19/2024","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-04-10"},{"id":"6aea670a-703a-4441-a9ff-cf2cf5b73ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479267","created_at":"2021-01-18T21:30:41.002Z","updated_at":"2024-07-02T16:35:13.759Z","phase":"Phase 2","brief_title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","source_id_and_acronym":"NCT04479267","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • cyclophosphamide intravenous • methylprednisolone sodium succinate • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/21/2020","start_date":" 08/21/2020","primary_txt":" Primary completion: 11/15/2025","primary_completion_date":" 11/15/2025","study_txt":" Completion: 11/15/2026","study_completion_date":" 11/15/2026","last_update_posted":"2024-03-20"},{"id":"29615e37-bb63-4054-a44c-541e878490a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05358379","created_at":"2024-02-07T19:21:22.852Z","updated_at":"2024-07-02T16:35:20.542Z","phase":"Phase 1/2","brief_title":"A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma","source_id_and_acronym":"NCT05358379","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" PLK1 • CDKN1A","pipe":" | ","alterations":" MYC expression","tags":["PLK1 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-02-07"},{"id":"8b4b85ac-4eb7-4ae3-8f3d-9a949ba6aaaa","acronym":"ALEXANDER","url":"https://clinicaltrials.gov/study/NCT03287817","created_at":"2021-01-18T16:14:33.110Z","updated_at":"2024-07-02T16:35:24.309Z","phase":"Phase 1/2","brief_title":"CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03287817 - ALEXANDER","lead_sponsor":"Autolus Limited","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • AUTO3"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 12/06/2023","primary_completion_date":" 12/06/2023","study_txt":" Completion: 12/06/2023","study_completion_date":" 12/06/2023","last_update_posted":"2024-01-08"},{"id":"300dc214-2f53-46f4-88db-099cbeecb27f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05755087","created_at":"2023-03-06T15:01:37.165Z","updated_at":"2024-07-02T16:35:24.905Z","phase":"Phase 1","brief_title":"Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05755087","lead_sponsor":"Lapo Alinari","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 03/05/2027","primary_completion_date":" 03/05/2027","study_txt":" Completion: 03/05/2027","study_completion_date":" 03/05/2027","last_update_posted":"2023-12-29"},{"id":"f819fdca-d47b-44d9-bff9-cba461ae961d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04214626","created_at":"2021-01-18T20:31:21.284Z","updated_at":"2024-07-02T16:35:27.097Z","phase":"Phase 2","brief_title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04214626","lead_sponsor":"Henan Cancer Hospital","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" BCL2 expression • MYC expression • TP53 expression","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • cyclophosphamide • epirubicin • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/02/2020","start_date":" 01/02/2020","primary_txt":" Primary completion: 11/29/2023","primary_completion_date":" 11/29/2023","study_txt":" Completion: 01/02/2025","study_completion_date":" 01/02/2025","last_update_posted":"2023-12-05"},{"id":"26065744-c262-4f87-91b1-e6294c2cfbc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323956","created_at":"2021-01-18T20:56:54.236Z","updated_at":"2024-07-02T16:35:31.265Z","phase":"Phase 1","brief_title":"Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04323956","lead_sponsor":"Mayo Clinic","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • parsaclisib (INCB50465) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2023-10-30"},{"id":"c9c366ea-e303-45e9-adda-89fe67d98af6","acronym":"VNC-152-101","url":"https://clinicaltrials.gov/study/NCT02635672","created_at":"2021-05-18T17:53:54.105Z","updated_at":"2024-07-02T16:35:39.904Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer","source_id_and_acronym":"NCT02635672 - VNC-152-101","lead_sponsor":"Vincerx Pharma, Inc.","biomarkers":" MYC","pipe":" | ","alterations":" MYC amplification • MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC amplification • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • enitociclib (VIP152)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/10/2016","start_date":" 02/10/2016","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-08-16"},{"id":"06f2e6a8-bdd2-4a87-bef8-65924c69c48b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04855253","created_at":"2021-04-22T20:53:39.288Z","updated_at":"2024-07-02T16:35:43.683Z","phase":"Phase 1/2","brief_title":"Study of E7777 Prior to Kymriah for R/R DLBCL","source_id_and_acronym":"NCT04855253","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYC","pipe":" | ","alterations":" MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-07-07"},{"id":"80832554-14d1-4109-8451-fa57e57f0cdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02391025","created_at":"2021-01-18T11:24:00.932Z","updated_at":"2024-07-02T16:35:45.319Z","phase":"Phase 1","brief_title":"Gallium-68 Citrate PET Used in Prostate Cancer","source_id_and_acronym":"NCT02391025","lead_sponsor":"Rahul Aggarwal","biomarkers":" MYC","pipe":" | ","alterations":" MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 05/28/2015","start_date":" 05/28/2015","primary_txt":" Primary completion: 06/15/2023","primary_completion_date":" 06/15/2023","study_txt":" Completion: 06/15/2023","study_completion_date":" 06/15/2023","last_update_posted":"2023-06-19"},{"id":"0a498da3-5052-4cfe-b07c-4435fee18fe1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04668365","created_at":"2021-01-19T20:44:06.435Z","updated_at":"2024-07-02T16:35:47.692Z","phase":"Phase 2","brief_title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04668365","lead_sponsor":"Henan Cancer Hospital","biomarkers":" MYC • BCL2 • CD79B • CD79A","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["MYC • BCL2 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • cytarabine • cyclophosphamide • oxaliplatin • Brukinsa (zanubrutinib) • epirubicin • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/25/2020","start_date":" 12/25/2020","primary_txt":" Primary completion: 12/25/2023","primary_completion_date":" 12/25/2023","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2023-05-18"},{"id":"a1df6c8b-2a63-439b-b62a-42b53c75ace9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05527912","created_at":"2022-09-06T17:03:03.863Z","updated_at":"2024-07-02T16:35:49.736Z","phase":"Phase 2","brief_title":"A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy","source_id_and_acronym":"NCT05527912","lead_sponsor":"Sun Yat-sen University","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-25"},{"id":"1ba19375-a278-4a1e-94fc-7fcdc21b85ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05100251","created_at":"2021-10-29T13:53:09.517Z","updated_at":"2024-07-02T16:35:57.046Z","phase":"Phase 1","brief_title":"Clinical Trial of WB100 on Advanced Solid Tumor","source_id_and_acronym":"NCT05100251","lead_sponsor":"Zhejiang University","biomarkers":" MYC • CA 19-9","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC positive","tags":["MYC • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WB100"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 10/25/2023","primary_completion_date":" 10/25/2023","study_txt":" Completion: 10/25/2023","study_completion_date":" 10/25/2023","last_update_posted":"2023-01-26"},{"id":"bcba688d-ccf2-45b4-927a-b48dc238e7e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05596097","created_at":"2022-10-27T15:58:27.582Z","updated_at":"2024-07-02T16:36:01.746Z","phase":"Phase 2","brief_title":"Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission","source_id_and_acronym":"NCT05596097","lead_sponsor":"LanZhou University","biomarkers":" TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/30/2022","start_date":" 10/30/2022","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2022-10-27"},{"id":"c70be74b-2caf-4912-96ba-c804e6129925","acronym":"NeoART","url":"https://clinicaltrials.gov/study/NCT02633098","created_at":"2021-01-18T12:48:25.777Z","updated_at":"2024-07-02T16:36:02.617Z","phase":"Phase 2","brief_title":"A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer","source_id_and_acronym":"NCT02633098 - NeoART","lead_sponsor":"St George's, University of London","biomarkers":" KRAS • BRAF • MYC • CCND1 • CD31 • PECAM1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • MYC expression • CCND1 expression","tags":["KRAS • BRAF • MYC • CCND1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • MYC expression • CCND1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/26/2017","start_date":" 04/26/2017","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2022-10-12"},{"id":"a4ec1eb0-717c-4885-999a-6e9126e9bc1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05498636","created_at":"2022-08-19T18:11:07.980Z","updated_at":"2024-07-02T16:36:05.112Z","phase":"Phase 1/2","brief_title":"SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression","source_id_and_acronym":"NCT05498636","lead_sponsor":"The Affiliated Hospital of Qingdao University","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC rearrangement • BCL2 rearrangement","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • etoposide IV • Xpovio (selinexor) • prednisone"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-08-19"},{"id":"99c6aa51-f895-426a-9d2b-d61b7aa32b3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05326035","created_at":"2022-04-13T11:55:07.809Z","updated_at":"2024-07-02T16:36:12.838Z","phase":"Phase 1/2","brief_title":"A Study of WJ05129 in Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05326035","lead_sponsor":"Suzhou Junjing BioSciences Co., Ltd.","biomarkers":" MYC","pipe":" | ","alterations":" MYC expression • RB1 negative","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression • RB1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WJ05129"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 04/30/2022","start_date":" 04/30/2022","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-04-13"},{"id":"33e7937d-fdc5-46f3-a2db-1aa51ac97e36","acronym":"CEMangio","url":"https://clinicaltrials.gov/study/NCT04873375","created_at":"2021-05-05T11:52:37.293Z","updated_at":"2024-07-02T16:36:17.624Z","phase":"Phase 2","brief_title":"Cemiplimab for Secondary Angiosarcomas","source_id_and_acronym":"NCT04873375 - CEMangio","lead_sponsor":"Radboud University","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1 expression • MYC expression","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2022-02-03"},{"id":"ad7962b6-d05e-4444-8c16-921ffca148eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03837873","created_at":"2021-01-18T18:56:43.079Z","updated_at":"2024-07-02T16:36:18.008Z","phase":"Phase 2","brief_title":"DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma","source_id_and_acronym":"NCT03837873","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" BCL2 • BCL6 • CD5","pipe":" | ","alterations":" BCL2 expression • MYC expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 01/21/2019","start_date":" 01/21/2019","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2022-01-26"}]